Intensity TherapeuticsINTS
13F holders, Q1 2026 (March 31)14holders
$5.88avg. 13F price*
At the end of Q1 2026, 14 institutions reported holding Intensity Therapeutics Inc. (INTS) in their 13F filings. The largest holders were Kingsbury Capital Investment Advisors LLC ($224K), Geode Capital Management, LLC ($153K) and Sapient Capital LLC ($153K).
- Company
- Intensity Therapeutics Inc.
- CUSIP
- 45828J202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 11 | $684K |
| Exits | 0 | $0 |
Ownership 14 holders
| Kingsbury Capital Investment Advisors LLC | 0.21% | — | 38,054 | $224K |
| Geode Capital Management, LLC | 0.00% | New | 26,019 | $153K |
| Sapient Capital LLC | 0.00% | New | 26,006 | $153K |
| Nano Cap New Millennium Growth Fund L P | 0.14% | New | 25,000 | $147K |
| Rothschild Wealth LLC | 0.01% | New | 23,294 | $137K |
| Vanguard Capital Management LLC | 0.00% | — | 16,841 | $99K |
| Mesirow Financial Investment Management, Inc. | 0.00% | New | 14,118 | $83K |
| Vanguard Fiduciary Trust Co. | 0.00% | — | 9,121 | $54K |
| NewEdge Advisors, LLC | 0.00% | New | 1,148 | $7K |
| Wells Fargo & Company | 0.00% | New | 200 | $1K |
| Osaic Holdings, Inc. | 0.00% | New | 200 | $1K |
| UBS Group AG | 0.00% | New | 192 | $1K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 67 | $394 |
| Morgan Stanley | 0.00% | New | 20 | $118 |
"% of holder's portfolio" is INTS's weight in each manager's 13F, not the share of Intensity Therapeutics Inc. the manager owns.